Market Cap
€342.0m
Last Updated
2019/10/16 21:20 UTC
Data Sources
Company Financials +
Executive Summary
Formycon AG engages in the development and marketing of biosimilar products.
Snowflake
Fundamentals
Adequate balance sheet with limited growth.
Share Price & News
How has Formycon's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.5%
FYB
-0.01%
DE Biotechs
4.1%
DE Market
1 Year Return
9.1%
FYB
3.1%
DE Biotechs
2.4%
DE Market
Return vs Industry: FYB exceeded the German Biotechs industry which returned 3.1% over the past year.
Return vs Market: FYB exceeded the German Market which returned 2.4% over the past year.
Shareholder returns
| FYB | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | -0.01% | 4.1% |
| 30 Day | 13.2% | -3.9% | 1.7% |
| 90 Day | 7.9% | -3.2% | 3.7% |
| 1 Year | 9.1%9.1% | 3.3%3.1% | 5.6%2.4% |
| 3 Year | 77.2%77.2% | 69.5%67.9% | 19.2%8.9% |
| 5 Year | 339.4%339.4% | 17.3%14.7% | 43.2%23.7% |
Price Volatility Vs. Market
How volatile is Formycon's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Announcing: Formycon (ETR:FYB) Stock Increased An Energizing 268% In The Last Five Years2 months ago | Simply Wall St
Does Formycon AG (ETR:FYB) Have A High Beta?Valuation
Is Formycon undervalued compared to its fair value and its price relative to the market?
6.87x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: Insufficient data to calculate FYB's fair value to establish if it is undervalued.
Significantly Undervalued: Insufficient data to calculate FYB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: FYB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: FYB is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate FYB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FYB is overvalued based on its PB Ratio (6.9x) compared to the DE Biotechs industry average (3.1x).
Next Steps
Future Growth
How is Formycon forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
-65.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FYB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FYB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FYB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FYB's revenue (28.5% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: FYB's revenue (28.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if FYB's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Formycon performed over the past 5 years?
35.0%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: FYB is unprofitable, but has reduced losses over the past 5 years at a rate of 35% per year.
Accelerating Growth: Unable to compare FYB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FYB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: FYB has a negative Return on Equity (-2.38%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: FYB is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: FYB is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Formycon's financial position?
Financial Position Analysis
Short Term Liabilities: FYB's short term assets (€28.3M) exceeds its short term liabilities (€3.5M)
Long Term Liabilities: FYB's short term assets (28.3M) exceeds its long term liabilities (702.1K)
Debt to Equity History and Analysis
Debt Level: FYB is debt free.
Reducing Debt: FYB had no debt 5 years ago.
Balance Sheet
Inventory Level: FYB has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if FYB's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if FYB has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if FYB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Formycon's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate FYB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate FYB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if FYB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FYB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FYB's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
What is the CEO of Formycon's salary, the management and board of directors tenure and is there insider trading?
4.6yrs
Average board tenure
CEO
Carsten Brockmeyer 0
6.5yrs
Tenure
Dr. Carsten Brockmeyer, PhD, has been Chief Executive Officer and Member of Executive Board at Formycon AG since April 16, 2013 and served as its Chairman of Executive Board. Dr. Brockmeyer has more than 2 ...
Board Age and Tenure
4.6yrs
Average Tenure
Experienced Board: FYB's board of directors are considered experienced (4.6 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Nicolas Combé
Co-Founder
- Tenure: 0yrs
Friedrich-Wilhelm Steinweg
Co-Founder
- Tenure: 0yrs
Carsten Brockmeyer
CEO & Member of Executive Board
- Tenure: 6.5yrs
Stefan Glombitza (54yo)
COO & Member of Executive Board
- Tenure: 3yrs
Board Members
Bernhard Hampl (69yo)
Member of Advisory Board
- Tenure: 5.6yrs
Gerhard Schaefer
Member of Advisory Board
- Tenure: 5.9yrs
Hermann Vogt
Deputy Chairman of Supervisory Board
- Tenure: 0yrs
Olaf Stiller (42yo)
Chairman of Supervisory Board
- Tenure: 0yrs
Peter Wendeln
Member of Supervisory Board
- Tenure: 0yrs
Johannes Buchner
Member of Advisory Board
- Tenure: 3.7yrs
Thomas Siklosi
Member of Advisory Board
- Tenure: 1.2yrs
Company Information
Formycon AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Formycon AG
- Ticker: FYB
- Exchange: XTRA
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €342.000m
- Shares outstanding: 10.00m
- Website: https://www.formycon.com
Number of Employees
Location
- Formycon AG
- Fraunhoferstrasse 15
- Martinsried
- Planegg
- Bavaria
- 82152
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| FYB | DB (Deutsche Boerse AG) | Yes | Bearer Shares | DE | EUR | Dec 2010 |
| FYB | XTRA (XETRA Trading Platform) | Yes | Bearer Shares | DE | EUR | Dec 2010 |
| 0W4N | LSE (London Stock Exchange) | Yes | Bearer Shares | GB | EUR | Dec 2010 |
| FYBD | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Bearer Shares | GB | EUR | Dec 2010 |
| FYB | ETLX (Eurotlx) | Yes | Bearer Shares | IT | EUR | Dec 2010 |
Biography
Formycon AG engages in the development and marketing of biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis 1, an ophthalmic drug used in the treatment of neovasc ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/16 21:20 |
| End of Day Share Price | 2019/10/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.